Medicus Pharma Seeks Orphan Drug Status for Skinject in Rare Cancer Condition

Medicus Pharma (NASDAQ: MDCX) has submitted an orphan drug designation application to the FDA for Skinject, targeting basal cell carcinoma in patients with Gorlin syndrome, a rare genetic disorder causing recurrent skin cancers. The move expands the company’s lead program into a high unmet need indication.

Gorlin syndrome patients can develop dozens to over 1,000 tumors over their lifetime, often requiring repeated surgeries. Skinject’s non-invasive approach could offer a significant alternative, reducing the burden of treatment and improving quality of life.

#MedicusPharma
#MDCX
#Biotech
#OrphanDrug
#SkinCancer
#BasalCellCarcinoma
#GorlinSyndrome
#ClinicalTrials
#Oncology
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#FDA
#NewsOut